These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 1551350)

  • 1. Alginic acid decreases postprandial upright gastroesophageal reflux. Comparison with equal-strength antacid.
    Castell DO; Dalton CB; Becker D; Sinclair J; Castell JA
    Dig Dis Sci; 1992 Apr; 37(4):589-93. PubMed ID: 1551350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children.
    Forbes D; Hodgson M; Hill R
    J Pediatr Gastroenterol Nutr; 1986; 5(4):556-9. PubMed ID: 3016226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study.
    De Ruigh A; Roman S; Chen J; Pandolfino JE; Kahrilas PJ
    Aliment Pharmacol Ther; 2014 Sep; 40(5):531-7. PubMed ID: 25041141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.
    Sweis R; Kaufman E; Anggiansah A; Wong T; Dettmar P; Fried M; Schwizer W; Avvari RK; Pal A; Fox M
    Aliment Pharmacol Ther; 2013 Jun; 37(11):1093-102. PubMed ID: 23600790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gaviscon in reflux symptoms. Results of a drug monitoring study].
    Hutt HJ; Tauber O; Flach D
    Fortschr Med; 1990 Oct; 108(31):598-600. PubMed ID: 2258131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).
    Wilkinson J; Abd-Elaziz K; den Daas I; Wemer J; van Haastert M; Hodgkinson V; Foster M; Coyle C
    Drug Dev Ind Pharm; 2019 Mar; 45(3):430-438. PubMed ID: 30470147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper.
    Deraman MA; Abdul Hafidz MI; Lawenko RM; Ma ZF; Wong MS; Coyle C; Lee YY
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1014-1021. PubMed ID: 32343001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of gastro-esophageal reflux using a potable gaviscon suspension].
    Guerre J; Neuman M; Bouchet J
    Med Chir Dig; 1982; 11(4):289-95. PubMed ID: 6287126
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparison between cisapride and Gaviscon with Carobel in the treatment of gastro-oesophageal reflux in infancy.
    Greally P; Hampton FJ; MacFadyen UM; Simpson H
    Ir Med J; 1992; 85(4 Suppl):14. PubMed ID: 1490841
    [No Abstract]   [Full Text] [Related]  

  • 10. [Can acid pocket-targeting alginate-antacid (Gaviscon Double Action) relieve upper gastrointestinal symptoms in gastro-oesophageal reflux disease?].
    Kim SE; Park MI
    Korean J Gastroenterol; 2014 Jun; 63(6):386-8. PubMed ID: 25097964
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapeutic procedures in gastroesophageal reflux disease].
    Tytgat GN
    Z Gastroenterol; 1986 Sep; 24 Suppl 2():40-4. PubMed ID: 2877526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined cimetidine-alginate antacid therapy versus single agent treatment for reflux oesophagitis: results of prospective double-blind randomised clinical trial.
    Eriksen CA; Cheadle WG; Cranford CA; Cuschieri A
    Ann Chir Gynaecol; 1988; 77(4):133-7. PubMed ID: 2855391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of Algicon versus Gaviscon in symptomatic gastro-oesophageal reflux.
    Ward AE
    Br J Clin Pract Suppl; 1989 Feb; 66():52-5; discussion 61-4. PubMed ID: 2556176
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of alginate in patients with GERD hiatal hernia matters.
    Vardar R; Keskin M; Valitova E; Bayrakci B; Yildirim E; Bor S
    Dis Esophagus; 2017 Oct; 30(10):1-7. PubMed ID: 28859383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children.
    Buts JP; Barudi C; Otte JB
    Eur J Pediatr; 1987 Mar; 146(2):156-8. PubMed ID: 3032640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of gastro-oesophageal reflux in volunteers assessed by ambulatory pH and gamma monitoring after treatment with either Liquid Gaviscon or Algicon Suspension.
    Washington N; Greaves JL; Iftikhar SY
    Aliment Pharmacol Ther; 1992 Oct; 6(5):579-88. PubMed ID: 1420749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients.
    Kwiatek MA; Roman S; Fareeduddin A; Pandolfino JE; Kahrilas PJ
    Aliment Pharmacol Ther; 2011 Jul; 34(1):59-66. PubMed ID: 21535446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Algicon in the management of gastro-oesophageal reflux.
    Lambert JR; Korman MG; Nicholson L
    Br J Clin Pract Suppl; 1989 Feb; 66():56-8; discussion 61-4. PubMed ID: 2556177
    [No Abstract]   [Full Text] [Related]  

  • 19. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.
    Mandel KG; Daggy BP; Brodie DA; Jacoby HI
    Aliment Pharmacol Ther; 2000 Jun; 14(6):669-90. PubMed ID: 10848650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mode of action alginic acid compound in the reduction of gastroesophageal reflux.
    Malmud LS; Charkes ND; Littlefield J; Reilley J; Stern H; Rosenberg R; Fisher RS
    J Nucl Med; 1979 Oct; 20(10):1023-8. PubMed ID: 231639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.